Sustained release preparation for tissue regeneration therapy
The present invention provides a microsphere with a slow-release period from about two weeks to about four weeks following administration, to enable a higher content of a drug to be included, to suppress an initial burst of the drug, and to maintain an optimal, effective blood concentration during the slow-release period. In a microsphere containing a drug and polylactic acid/glycolic acid (PLGA) copolymer, the amount of PLGA copolymer per part by weight of the drug is from about 3 to about 10 parts by weight; the average particle size of the microsphere is from about 20 to about 50 μm; and (3) the PLGA copolymer has a weight-average molecular weight from about 10,000 to about 50,000 and a PLGA compositional ratio from about 75/25 to about 50/50. The microsphere promotes the production of various endogenous repair factors useful against various tissue disorders.
1. A two to four-week long-acting microsphere,
comprising ({5-[2-({[(1E)-phenyl(pyridin-3-yl)methylene]amino}oxy)ethyl]-7,8-dihydronaphthalen-1-yl}oxy)acetic acid or a salt thereof as a drug and a lactic acid/glycolic acid copolymer, wherein
(i) an amount of lactic acid/glycolic acid copolymer per part by weight of the drug is from 3 to 10 parts by weight,
(ii) the microsphere has an average particle size of from 20 to 50 μm, and
(iii) the lactic acid/glycolic acid copolymer has a weight-average molecular weight of from 10,000 to 50,000 and a lactic acid/glycolic acid compositional ratio of from 75/25 to 50/50.
2. The microsphere according to claim 1 , wherein the content of lactic acid/glycolic acid copolymer per part by weight of the drug is from 4 to 8 parts by weight.
3. The microsphere according to claim 1 , wherein the microsphere has an average particle size of from 25 to 35 μm.
4. The microsphere according to claim 1 , wherein the lactic acid/glycolic acid copolymer ratio is 50/50.
5. A method of treating arteriosclerosis obliterans, stroke, pulmonary fibrosis, pulmonary hypertension, asthma, diabetes and complications thereof, angina, myocardial infarction, heart failure, dilated cardiomyopathy, renal failure, osteoarthritis, rheumatoid arthritis or osteoporosis, comprising administering to a patient, the microsphere of claim 1 .
6. A two-week long-acting microsphere,
comprising ({5-[2-({[(1E)-phenyl(pyridin-3-yl)methylene]amino}oxy)ethyl]-7,8-dihydronaphthalen-1-yl} oxy)acetic acid or a salt thereof as a drug and a lactic acid/glycolic acid copolymer, wherein
(i) an amount of lactic acid/glycolic acid copolymer per part by weight of the drug is from 4 to 8 parts by weight,
(ii) the microsphere has an average particle size of from 25 to 35 μm, and
(iii) the lactic acid/glycolic acid copolymer has a weight-average molecular weight of from 10,000 to 30,000 and a lactic acid/glycolic acid compositional ratio of 50/50.
7. A four-week long-acting microsphere,
comprising ({5-[2-({[(1E)-phenyl(pyridin-3-yl)methylene]amino}oxy)ethyl]-7,8-dihydronaphthalen-1-yl}oxy)acetic acid or a salt thereof as a drug and a lactic acid/glycolic acid copolymer, wherein
(i) an amount of lactic acid/glycolic acid copolymer per part by weight of the drug is from 4 to 8 parts by weight,
(ii) the microsphere has an average particle size of from 25 to 35 μm, and
(iii) the lactic acid/glycolic acid copolymer has a weight-average molecular weight of from 30,000 to 50,000 and a lactic acid/glycolic acid compositional ratio of 50/50.